Zarrabi, Morteza
Shahrbaf, Mohammad Amin
Nouri, Masoumeh
Shekari, Faezeh
Hosseini, Seyedeh-Esmat
Hashemian, Seyed-Mohammad Reza
Aliannejad, Rasoul
Jamaati, Hamidreza
Khavandgar, Naghmeh
Alemi, Hediyeh
Madani, Hoda
Nazari, Abdoreza
Amini, Azadeh
Hassani, Seyedeh Nafiseh
Abbasi, Fatemeh
Jarooghi, Neda
Fallah, Nasrin
Taghiyar, Leila
Ganjibakhsh, Meysam
Hajizadeh-Saffar, Ensiyeh
Vosough, Massoud
Baharvand, Hossein
Funding for this research was provided by:
Cell Tech Pharmed
Royesh Venture Capital
Article History
Received: 19 November 2022
Accepted: 15 June 2023
First Online: 26 June 2023
Declarations
:
: We conducted this study in accordance with the Helsinki declaration [CitationRef removed]. The informed consent was received from all patients. The researchers ensured that patient information remained confidential. The study was approved in the ethical committee of the National Institute for Medical Research Development (NIMAD), Tehran, Iran, on March 12th 2020, with the title of “Mesenchymal stem cell therapy for ARDS in Coronavirus infection with two protocols: A randomized, placebo-controlled Phase 1 and 2 clinical trial” and the registration number of IR.NIMAD.REC.1398.412. The registration can be found at ExternalRef removed. Also, the clinical trial protocol was registered by the Iranian Registry of Clinical Trials (IRCT), on April 13th 2020, with the title of “Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2–3 Clinical Trial” and trial ID code of IRCT20200217046526N2. The registration can be found at ExternalRef removed.
: Not applicable.
: EHS and MV were collaborating for the industrial manufacturing of the products used in this work, and they declare no financial interest that could have appeared to influence the data reported in this paper. The remaining authors have no conflicts of interest to declare.